论文部分内容阅读
用经门静脉注射转铁蛋白受体单抗－阿霉素（ＯＫＴ９ＡＤＭ）偶联物导向化疗结合肝动脉栓塞治疗１５例不能切除的原发性肝癌患者（第一组），同期另外１０例患者行肝动脉栓塞＋门静脉ＡＤＭ化疗作对照（第二组）。结果显示：第一组门静脉血内阿霉素浓度明显高于外周血和第二组门静脉血内阿霉素浓度。彩色多普勒超声引导癌栓穿刺活检显示，经门静脉导向化疗后，第一组有２例门静脉癌栓出现坏死，临床观察提示：经门静脉注射ＯＫＴ９ＡＤＭ偶联物对不能切除的肝癌的治疗是有效的，尤其是对门静脉癌栓的治疗可能比门静脉ＡＤＭ化疗更有效，但其远期疗效需进一步随机对照研究来评价。
Using portal vein injection of transferrin receptor monoclonal antibody-Adriamycin (OKT9-ADM) conjugate-directed chemotherapy in combination with hepatic artery embolization to treat 15 patients with unresectable primary liver cancer (group 1), while another 10 patients in the same period Patients underwent hepatic artery embolization plus portal vein ADM chemotherapy as a control (Group 2). The results showed that the concentration of doxorubicin in the first group of portal vein blood was significantly higher than that of peripheral blood and the second group of doxorubicin in portal vein blood. Color Doppler ultrasound-guided tumor embolization biopsy showed that after portal vein-guided chemotherapy, there were 2 cases of portal vein tumor emboli necrosis in the first group. Clinical observations suggest that treatment of unresectable liver cancer by portal vein injection of OKT9-ADM conjugate It is effective, especially for the treatment of portal vein tumor thrombus may be more effective than portal vein ADM chemotherapy, but its long-term efficacy needs further randomized controlled studies to evaluate.